

Francesca Pica

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6175992/publications.pdf>

Version: 2024-02-01

55
papers

1,401
citations

257357

24
h-index

360920

35
g-index

55
all docs

55
docs citations

55
times ranked

1762
citing authors

#	ARTICLE	IF	CITATIONS
1	Microbial contamination of the surface of mobile phones and implications for the containment of the Covid-19 pandemic. <i>Travel Medicine and Infectious Disease</i> , 2020, 37, 101870.	1.5	5
2	Taking Screenshots of the Invisible: A Study on Bacterial Contamination of Mobile Phones from University Students of Healthcare Professions in Rome, Italy. <i>Microorganisms</i> , 2020, 8, 1075.	1.6	16
3	Viruses of Respiratory Tract: an Observational Retrospective Study on Hospitalized Patients in Rome, Italy. <i>Microorganisms</i> , 2020, 8, 501.	1.6	10
4	High expression of Endogenous Retroviruses from intrauterine life to adulthood in two mouse models of Autism Spectrum Disorders. <i>Scientific Reports</i> , 2018, 8, 629.	1.6	24
5	Herpes zoster in frail elderly patients: prevalence, impact, management, and preventive strategies. <i>Aging Clinical and Experimental Research</i> , 2018, 30, 693-702.	1.4	28
6	Thymosin $\hat{\pm}$ 1 expands deficient IL-10-producing regulatory B cell subsets in relapsing/remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 127-139.	1.4	23
7	Antifungal activity of <i>Cardiospermum halicacabum</i> L. (Sapindaceae) against <i>Trichophyton rubrum</i> ; occurs through molecular interaction with fungal Hsp90. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2185-2193.	2.0	27
8	Serum thymosin alpha 1 levels in normal and pathological conditions. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 13-21.	1.4	12
9	Deciphering cellular biological processes to clinical application: a new perspective for $\hat{\pm}$ 1 treatment targeting multiple diseases. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 23-31.	1.4	11
10	Potential mechanism of thymosin $\hat{\pm}$ 1-membrane interactions leading to pleiotropy: experimental evidence and hypotheses. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 33-42.	1.4	4
11	Thymosin $\hat{\pm}$ 1 Interacts with Hyaluronic Acid Electrostatically by Its Terminal Sequence LKEKK. <i>Molecules</i> , 2017, 22, 1843.	1.7	9
12	Thymosin $\hat{\pm}$ 1 Interacts with Hyaluronic Acid Electrostatically by Its Terminal Sequence LKEKK. <i>Molecules</i> , 2017, 22, 1843.	1.7	1
13	Clinical features and outcome of hospitalized patients with HSV-1 DNA in the lower respiratory tract. <i>New Microbiologica</i> , 2017, 40, 107-112.	0.1	1
14	Thymosin $\hat{\pm}$ 1 Interacts with Exposed Phosphatidylserine in Membrane Models and in Cells and Uses Serum Albumin as a Carrier. <i>Biochemistry</i> , 2016, 55, 1462-1472.	1.2	20
15	New studies about the insertion mechanism of Thymosin $\hat{\pm}$ 1 in negative regions of model membranes as starting point of the bioactivity. <i>Amino Acids</i> , 2016, 48, 1231-1239.	1.2	13
16	Antitumor effects of the benzophenanthridine alkaloid sanguinarine: Evidence and perspectives. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 30.	0.8	67
17	Transcriptional Activity of Human Endogenous Retroviruses in Human Peripheral Blood Mononuclear Cells. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	46
18	Thymosin $\hat{\pm}$ 1 inserts N terminus into model membranes assuming a helical conformation. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 71-81.	1.4	16

#	ARTICLE	IF	CITATIONS
19	Historical review on thymosin α 1 in oncology: preclinical and clinical experiences. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 31-39.	1.4	28
20	Thymosin α 1; Activates Complement Receptor-Mediated Phagocytosis in Human Monocyte-Derived Macrophages. <i>Journal of Innate Immunity</i> , 2014, 6, 72-88.	1.8	29
21	One-year follow-up of patients with long-lasting post-herpetic neuralgia. <i>BMC Infectious Diseases</i> , 2014, 14, 556.	1.3	12
22	A Systematic Analysis of Host Factors Reveals a Med23-Interferon- γ Regulatory Axis against Herpes Simplex Virus Type 1 Replication. <i>PLoS Pathogens</i> , 2013, 9, e1003514.	2.1	88
23	Antitumor effects of the benzophenanthridine alkaloid sanguinarine in a rat syngeneic model of colorectal cancer. <i>Anti-Cancer Drugs</i> , 2012, 23, 32-42.	0.7	36
24	Thymosin α 1 and cancer: action on immune effector and tumor target cells. <i>Annals of the New York Academy of Sciences</i> , 2012, 1269, 26-33.	1.8	62
25	Thymosin α 1 as a stimulatory agent of innate cell-mediated immune response. <i>Annals of the New York Academy of Sciences</i> , 2012, 1270, 13-20.	1.8	29
26	HERVs Expression in Autism Spectrum Disorders. <i>PLoS ONE</i> , 2012, 7, e48831.	1.1	55
27	Public awareness and knowledge of herpes labialis. <i>Journal of Medical Virology</i> , 2012, 84, 132-137.	2.5	10
28	Frequency of Herpes Zoster Recurrence. <i>Mayo Clinic Proceedings</i> , 2011, 86, 586.	1.4	11
29	Interferon- γ in immunocompetent individuals with a history of recurrent herpes labialis. <i>Antiviral Therapy</i> , 2010, 15, 737-743.	0.6	13
30	Increased levels of p70S6 phosphorylation in the G93A mouse model of Amyotrophic Lateral Sclerosis and in valine-exposed cortical neurons in culture. <i>Experimental Neurology</i> , 2010, 226, 218-230.	2.0	37
31	Clinical and psychosocial correlates of post-herpetic neuralgia. <i>Journal of Medical Virology</i> , 2008, 80, 1646-1652.	2.5	65
32	Transmission of human herpesvirus 8: an update. <i>Current Opinion in Infectious Diseases</i> , 2007, 20, 152-156.	1.3	74
33	Clinical and psychosocial correlates of acute pain in herpes zoster. <i>Journal of Clinical Virology</i> , 2007, 38, 275-279.	1.6	25
34	Thymosin Alpha 1. <i>Annals of the New York Academy of Sciences</i> , 2007, 1112, 225-234.	1.8	41
35	Effect of extremely low frequency electromagnetic fields (ELF-EMF) on Kaposi's sarcoma-associated herpes virus in BCBL-1 cells. <i>Bioelectromagnetics</i> , 2006, 27, 226-232.	0.9	3
36	Human Herpesvirus 8 DNA in Serum During Seroconversion in Allogeneic Bone Marrow Transplant Recipients. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1008-1011.	3.0	21

#	ARTICLE	IF	CITATIONS
37	Antitumour effect of OM-174 and Cyclophosphamide on murine B16 melanoma in different experimental conditions. <i>International Immunopharmacology</i> , 2005, 5, 1205-1212.	1.7	54
38	Cidofovir on HHV-8 in BCBL-1 cells. <i>Antiviral Therapy</i> , 2004, 9, 823-5.	0.6	2
39	Cidofovir on Hhv-8 in Bcbl-1 Cells. <i>Antiviral Therapy</i> , 2004, 9, 823-825.	0.6	4
40	Thymosin $\hat{\pm}$ 1 in combination with cytokines and chemotherapy for the treatment of cancer. <i>International Immunopharmacology</i> , 2003, 3, 1145-1150.	1.7	37
41	Antiviral treatment of varicella in pediatric practice in the Latium region of Italy: results of an observational study. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 739-742.	1.1	5
42	Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. <i>International Journal of Immunopharmacology</i> , 2000, 22, 1067-1076.	1.1	44
43	Autocrine nerve growth factor is essential for cell survival and viral maturation in HHV-8-infected primary effusion lymphoma cells. <i>Blood</i> , 2000, 95, 2905-2912.	0.6	13
44	$\hat{\sup}12$ -Prostaglandin J $\sub{2}$ Is a Potent Inhibitor of Influenza A Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 200-204.	1.4	31
45	Neutralizing Antibody Response against Human Cytomegalovirus in Allogeneic Bone Marrow Transplant Recipients. <i>Journal of Infectious Diseases</i> , 1999, 180, 1747-1748.	1.9	14
46	Combination therapy with BRMs in cancer and infectious diseases. <i>Mechanisms of Ageing and Development</i> , 1997, 96, 103-116.	2.2	6
47	Antitumor Effect of Thymosin $\hat{\pm}$ 1/Interleukin-2 or Thymosin $\hat{\pm}$ 1/Interferon $\hat{\pm}$ 1, $\hat{\pm}$ 2 Following Cyclophosphamide in Mice Injected with Highly Metastatic Friend Erythroleukemia Cells. <i>Journal of Immunotherapy</i> , 1993, 13, 7-17.	1.2	36
48	Combination Therapy with Thymosin $\hat{\pm}$ 1 and Cytokines in the Treatment of Cancer and Infectious Diseases. , 1993, , 49-60.		3
49	Efficacy of the Combined Treatment with Fluconazole and Thymosin $\hat{\pm}$ 1 Against <i>Candida albicans</i> Infection in Morphine-Treated Mice. , 1993, , 189-194.		0
50	Thymosin alpha one restores murine T-cell-mediated responses inhibited by In vivo cocaine administration. <i>International Journal of Immunopharmacology</i> , 1992, 14, 1-9.	1.1	16
51	In vivo cocaine administration influences lymphokine production and humoral immune response. <i>Immunologic Research</i> , 1992, 11, 74-79.	1.3	39
52	Combination therapy with thymosin $\hat{\pm}$ 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the lewis lung carcinoma in mice. <i>International Journal of Cancer</i> , 1992, 50, 493-499.	2.3	48
53	Rationale for Therapeutic Approaches with Thymosin $\hat{\pm}$ 1, Interleukin 2 and Interferon in Combination with Chemotherapy. , 1992, , 275-281.		4
54	Combination treatment using thymosin $\hat{\pm}$ 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. <i>Cancer Immunology, Immunotherapy</i> , 1990, 32, 154-160.	2.0	53

#	ARTICLE	IF	CITATIONS
55	Cytomegalovirus infection in day care centers in Rome, Italy: Viral excretion in children and occupational risk among workers. <i>Journal of Medical Virology</i> , 1988, 26, 119-125.	2.5	20